




J. Afr. Ass. Physiol. Sci. 8 (1): 8-15 July 2020 
 
Journal of African Association of Physiological Sciences 







TxA2 Receptor Antagonist (SQ29548) attenuates Endothelium-
Independent recovery from Thromboxane A2 Contraction of 
Isolated Rabbit Aorta 
 
A.M. Danborno1,2*, P.L Monnet2,3 and J.A. Orr2 
Departments of  1Physiology, 2Molecular Biosciences, 1Faculty of Basic Medical Sciences, Bingham University, 
Karu, Nigeria, 2University of Kansas, Lawrence KS, 66045 and 3Truman Medical Center, University of Missouri- 
Kansas City, Department of OBGYN, 2301 Holmes Street, Kansas City, MO 64108, USA 
 
Keywords: 
Thromboxane A2, mimetic, 
receptor antagonist, 
smooth muscle, 
























Background: Thromboxane A2 (TxA2) is a potent constrictor of blood vessels and has been 
implicated in the pathogenesis of some cardiovascular diseases. This study examined an 
intervention that can be used to displace the tight binding of thromboxane mimetic, U46619 to 
the thromboxane (TP) receptors thereby bringing about a faster relaxation. We hypothesized that 
the prolonged contraction of U46619 stimulated VSM could be due, in some part, to a tight 
binding between U46619 and the TP receptor, leading to continual activation of the receptor. 
Methods: Aortic rings were obtained from euthanized rabbit (n ═ 28) and placed in an organ 
bath system with temperature maintained at 37OC and contractile responses to the thromboxane 
mimetic, U46619 (0.5 µM) measured.  Following a maximum contraction, SQ29548 was added, 
and the vessels allowed to relax to baseline. We then investigated whether the displacement of 
U46619 and faster relaxation brought about by SQ29548 was dependent on the release of NO 
from the endothelium. Results: Following treatment with SQ29548 (3.0 µM) the aortic vessels 
relaxed at a significantly higher rate (0.23 ± 0.04 g/min) compared to the vehicle-treated vessels 
(0.03 ± 0.01 g/min) (P < 0.0001). Vessels treated with an inhibitor of NO production (L-NAME) 
or vessels where the endothelium was mechanically removed showed the same response to rate 
of relaxation as vessels treated with the vehicle or vessels in which the endothelium was not 
denuded (P = 0.93 and P = 0.38). Conclusion: Focusing on strategies to speed up relaxation of 
a contracted vessel adds to the significance of this work. Results from our experiments suggest 
that administration of SQ29548 may be useful in relaxing a vessel that is already contracted by 
TxA2, for example, a vessel in spasm and also in an atherosclerotic vessel in which NO the 
relaxing factor in vascular smooth muscle has been affected.   
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INTRODUCTION   
Thromboxane A2 (TxA2) is one of the endogenously 
occurring vascular smooth muscle contracting and 
platelet activating substances (Orr et al., 1993; Leung et 
al., 2010; Wacker et al., 2012). It also induces 
contraction of smooth muscles in the airways of the 
lungs (Liu et al., 1997).  Thromboxane A2 (TxA2) has 
been implicated in some cardiovascular abnormalities, 
such as hypertension (Davi and Patrono, 2007 and 
Mckenzie et al., 2009).  It produces its contractile 
properties by binding to TP receptor. The TP receptor is 
a protein that is encoded by the TBXA2R gene in humans 
and it is one among the five classes of prostanoid 
receptors (Devillier and Bessard, 1997). It was the first 
eicosanoid receptor cloned (Rolin et al., 2006), deriving 
its name from the endogenous ligand thromboxane A2 
and it is G-protein-coupled (McKenzie et al., 2009 and 
Marcio et al., 2011). 
One of the important physiological/pathophysiological 
actions of TXA2 is platelet activation, leading to platelet 
shape change, aggregation and secretion, which promote 
thrombus formation (Navarro-Nunez et al., 2007). 
Thrombus formation mediated by TxA2– induced 
platelet aggregation and vasoconstriction sometimes 
causes acute myocardial infarction and cerebral 
infarction, which are prevented by inhibition of TxA2 
synthesis and/or use of TP antagonists (Nakahata, 2008 
and Davi et al., 2012). One stable TP antagonist, 
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SQ29548 is a synthetic compound that binds to, but does 
not activate TP receptor and thereby inhibits its 
activation by activating ligands. (Ogletree et al., 1985). 
An earlier study (Ogletree et al., 1998) has demonstrated 
an antagonistic effect of SQ29548 on TP receptor. Other 
studies have also reported that dysfunction of the local, 
humoral, and neurogenic regulation of the molecular 
pathways involved in thoracic aorta vascular smooth 
muscle contraction, has been shown to contribute to 
numerous pathologies, including hypertension and 
arterial stiffness (Lindesay et al., 2010, Leloup et al., 
2015, Leloup et al., 2019). The imbalance between the 
prostanoids pathway and NO pathway has also been 
attributed to the development of some cardiovascular 
diseases (Davi et al., 2012 and Silva et al., 2017). 
In this study, we focused on a pharmacological 
intervention that could attenuate the rate of recovery 
from U46619 induced vascular smooth muscle 
contraction. We hypothesized that the prolonged 
contraction of U46619 stimulated VSM could be due, in 
some part, to a tight binding between U46619 and the TP 
receptor, leading to sustained activation of the receptor. 
By dissociating U46619 from the TP receptor using a 
receptor antagonist, the VSM would conceivably have a 
faster rate of recovery from sustained contraction 
induced by U46619 in both endothelium-intact (E+) and 
endothelium-denuded (E-) vessels. A TP agonist 
produced by the vascular endothelium, especially under 
pathological conditions can cause endothelium 
dependent contraction and thereby contribute to 
endothelial dysfunction observed in diseases such as 
hypertension and diabetes (Feletou et al., 2010). TP 
antagonists are therefore of vital importance in 
counteracting these effects. SQ29548 is a synthetic 
compound that binds to, but does not activate TP 
receptor and thereby inhibits its activation by activating 
ligands. It is an antagonist that binds specifically to the 
TP receptor and blocks TxA2 and U46619 from binding 
(Ogletree et al., 1985 and Krauss et al., 1996). Without 
the continual stimulation of the intracellular events that 
lead to calcium release and smooth muscle contraction, 
the vessels should relax more quickly. The binding 
affinity (Ki) of SQ29548 to the TP receptor in human 
platelet membranes is 7.34 nm, while the Ki of U46619 
to the TP receptor in human platelet membranes is 17.7 
nm (Hedberg et al., 1988). Given this, the concentration 
of SQ29548 used (3.0 µM) should be sufficient to 
dissociate U46619 (0.5 µM) from the receptor and block 
the effects of the TxA2 mimetic. 
 
METHODS 
New Zealand white rabbits (average wt. 3.75 kg, n= 28) 
of both sexes were euthanized according to Institutional 
Animal Care and Use Committee (IACUC) Protocol 42–
02 of the University of Kansas, USA. Following 
euthanasia of the animal, the thorax was opened and a 
segment of the descending trunk of the aorta was 
excised, placed in a physiological salt solution. The 
aortic rings were cleaned of excess connective tissue and 
cut into four or six ring segments of 2-3 mm each and 
then suspended in organ baths (Radnoti, Monrovia CA, 
USA). The organ bath (25 ml) contained physiological 
buffer solution maintained at 37 oC that was aerated with 
a gas mixture of 95% O2 and 5% CO2. The aortic rings 
were suspended from a stationary hook within the organ 
bath and connected to a force transducer that recorded 
the tension generated by the vessels. Tension was 
calibrated prior to each experiment with a known force 
(5 g). The contractions were recorded with the use of the 
data acquisition software power lab (AD Instruments, 
Colorado Springs, CO, USA). The aortic vessels were 
allowed to equilibrate for 60 minutes in the 
physiological salt solution at a tension of approximately 
2 g. With the exception of exposure to high KCl (60 
mM), all drugs were added directly to physiological salt 
solution of the organ bath. Prior to the initial treatment 
with high KCl, the tension on the vessels was maintained 
at 2 g in order to provide a stable tonic baseline tension 
to the aortic rings. Following treatment with either high 
KCl or U46619, sufficient time was allowed so that the 
tension of vessels returned back to the baseline value of 
2 g. Two series of experiments were carried out: 
 
Series 1: Experiments were designed to examine the 
relaxation of intact vessels following contraction to the 
thromboxane A2 mimetic (U46619).  After equilibration 
with the physiological salt solution, the tension on the 
vessel was adjusted to 2 g and the vessels were exposed 
to a solution containing high KCl (60 mM) to establish a 
baseline contraction. The organ bath was then drained of 
all fluid and replaced with physiological salt solution. 
Following relaxation of the vessels to baseline, they 
were stimulated with the thromboxane A2 mimetic 
U46619 (0.5 µM). Following a steady maximal 
contraction, SQ29548 or a vehicle (DI H2O) was added 
to the respective organ baths and the ensuing relaxation 
of vessels to baseline tension recorded.  
 
Series 2a: A second series of experiments was designed 
to examine the response of U46619 relaxation following 
treatment with the TxA2 receptor antagonist (SQ29548 
3.0 uM) in the presence (E+) and absence (E-) of the 
endothelium. Denudation of the endothelium was 
achieved with forceps and Q-tips. After the mechanical 
removal of the endothelium, the vessels were 
equilibrated in physiological salt solution for 60 min 
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after which the physiological salt was replaced with a 
physiological buffer solution containing 60 mM KCl and 
the contractile response to high KCl solution was 
recorded. To evaluate the involvement of TxA2 mimetic, 
TxA2 receptor antagonist and the endothelium, at the 
peak of the contractile response to U46619 the aortic 
rings were exposed to SQ29548 (3.0 μM), TxA2 
receptor antagonist , until the vessels reached the base 
line. SQ 29548 relaxation was calculated as a difference 
in rate of relaxation per minute. In order to verify the 
efficacy of removal of the endothelium or treatment with 
the NO synthase inhibitor the vessels were then allowed 
to return to base line tension, after which they were 
contracted by PE (1.0 μM) and then relaxed by Ach (1.0 
μM). 
 
Series 2b: The final series of experiments were designed 
to examine if the inhibition of NO synthesis altered the  
effect of SQ29548 on the relaxation phase following a 
TxA2 induced contraction. NO synthesis was inhibited in 
the endothelium using L-NAME, a specific inhibitor of 
nitric oxide synthesis. After the initial incubation of the 
blood vessel rings in L- NAME (100 μM) for 30 min, 
U46619 (0.5 μM)  was then added to the buffer solution 
and the vessels were then allowed to contract to a 
maximum level. At the peak of the contractile response 
to U46619, the aortic rings were exposed to SQ29548 so 
as to evaluate the association of TxA2 mimetic, TxA2 
receptor antagonist and production of NO.  After the 
vessels reached the baseline, the solution containing 
SQ29548 was replaced with physiological salt solution. 
SQ29548 relaxation was calculated as a difference in 
rate of relaxation per minute.  
Administration of PE, followed by Ach, was used to test 
the efficacy of L-NAME with regards to inhibition of 
NO synthesis. After all vessels had relaxed to 2 g, the 
vessels were treated with final high KCl and allowed to 
maximally contract.   
 
Statistical analyses 
Data were collected by using chart for Windows 
(ADInstruments). The contraction in response to the 
initial high KCl (60 mM) was designated arbitrarily as 
100% and all subsequent contractions were compared to 
this contraction. This procedure allowed us to 
standardize data from vessel segments of different sizes 
and reactivity.  Data were expressed as mean ± standard 
error of mean (SEM). Unpaired t-tests were also used to 
compare the differences in the contraction and relaxation 
of aortic vessels in the presence and absence of the 
endothelium. SigmaStat 3.5 for Windows (Systat Inc., 
San Rafael, CA) was used for the data analyses and 
graphs were drawn using Microsoft Excel 2016. One-
way analysis of variance (ANOVA) was performed to 
determine the statistical significance between the 
relative strength of contraction of drug treated versus 
control vessels. A value of P < 0.05 was considered 
statistically significant. 
 
Drugs and solutions 
The composition of physiological buffer was (mM): 
NaCl 118.4, KCl 4.7, CaCl2 2.5, NaHCO3 25, KH2PO4 
1.2, MgSO4 1.2, and dextrose 11, and pH was adjusted 
to 7.4 to mimic physiological conditions.  
The composition of 60 mM KCl physiological buffer 
solution was (mM): NaCl 63.1, KCl 60, CaCl2 2.5, 
NaHCO3 25, KH2PO4 1.2, MgSO4 1.2, and dextrose 11.  
U46619 (9,11-dideoxy-9α,11α-methanoepoxy-prosta-
5Z,13E-dien-1-oic acid), L – NAME (Nω-nitro-L-
arginine methyl ester hydrochloride) and TP antagonist 
SQ 29548 ([1S-[1α,2α(Z),3α,4α]]-7-[3-[[2-
[(phenylamino)carbonyl]hydrazino]methyl]-7-
oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid) were 
purchased from Cayman Chemical (Ann Arbor, MI, 
USA).   PE (L-Phenylephrine hydrochloride) and Ach 
(Acetylcholine hydrochloride) were purchased from 
Sigma-Aldrich (St Louis, MO, USA). U46619 was 
dissolved in 100% ethanol and further diluted with 
normal saline to a concentration of 5µg/mL. L–NAME 
20 mg was dissolved in 20 ml DMSO to a final 
concentration of 100 μM on the day of experiment.  
SQ29548 and ACh were both dissolved in deionized 
(DI) H2O to a final concentration of 3.0 µM and 10 µM, 
respectively. PE was also dissolved in DI H2O to a final 
concentration of 10 µM /ml 
 
RESULTS 
Representative tracings from aortic vessels exposed to 
various treatments and drug interventions are shown in 
Figs. 1-3. In Fig. 1, treatment with a strong depolarizing 
agent (high KCl) leads to constriction of the vessel. The 
vessel relaxes when the high KCl is drained from the 
organ bath and replaced with physiological salt solution 
(termed ‘wash’ on the x-axis).  
A stronger contraction occurs when the vessel is treated 
with the TxA2 mimetic, U46619. However, when the 
buffer containing U46619 is removed and replaced with 
physiological salt solution, the vessel remains contracted 
and the time to baseline relaxation is significantly 
lengthened compared to the high KCl treatment (Fig.1 
panel A). Quantifying the rate of relaxation of the 
vessels was accomplished by assuming a linear decrease 
in force from the initial removal of U-46619 from the 
bath to the return to baseline tension (2 g). This 
procedure is illustrated in Fig. 1, panel A. The rate of 
relaxation for this aortic vessel was calculated as 0.045 
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Fig.1: Panel A, A linear line was extrapolated from the point at which the vessel was treated with U46619 to the point at which 
the vessel reached 2 g of tension. A rate of relaxation was found by dividing the change in force (F) by the change in time (T). 
Panel B: Vessel treated with SQ29548 following treatment with U46619 (n= 6) 
 
 
Fig. 2: Panel A, Relaxation responses induced by SQ29548 in isolated aortic vessels pre-contracted with U46619. Tracings are 
from endothelium-intact vessel, control E+ . Panel B, Endothelium denuded E- vessel (n = 11) 
 
g/min. This procedure accounts for any differences in the 
steady state maximal contraction by U-46619 between 
vessel segments.  
 
Aortic vessels treated with SQ29548 relaxed at a rate of 
0.23 g/min (± 0.04) (Fig. 1 panel B and Fig. 4), while 
untreated vessels (control) relaxed at a slower rate of  
 
0.03 g/min (±0.01) (Fig. 1 panel A and Fig 4) (P<0.0001: 
Fig. 4).  
The absence of NO in the endothelium had no effect on 
the actions of SQ29548. The response of U46619 was 
sensitive to the binding of the receptor antagonist 
SQ29548 inhibition both in denuded aortic rings (Fig. 3; 
panel B) and in L-NAME treated aortic rings (Fig. 2;  
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Fig. 3: Panel A, Tracings are from DMSO treated (vehicle for L-NAME) control E+;  Panel B,  L-NAME treated E-  (n=11) 
 
panel B). Relaxation caused by SQ29548 was not 
dependent on the presence or absence of endogenous 
NO, so there was no significant difference in the rate of 
relaxation between E+ and E- vessels both in 
endothelium-denuded vessels (P=0.38) and L-NAME 
treated aortic rings (P=0.93) (Fig. 5).  
 
 
Fig. 4: The relaxation rate of treated (SQ29543= 3.0 µM) and 
untreated (control) vessels following treatment with U46619 
(0.5 µM; n= 6). 
 
When SQ29548 is administered, the final KCl 
contractions were not affected (Fig. 6; panel A). In both 
forceps denuded endothelium and L-NAME treated 
aortic rings, U46619, PE and the final KCl contractions 
were not attenuated in E+ vessels and E- vessels (Fig. 6; 
panel B and C).  
 
DISCUSSION  
Vascular smooth muscle cells (VSMCs) stimulated with 
U46619 remain contracted longer than VSMCs treated 
with other vasoconstrictive agents such as PE and high 
KCl (Neppl et al., 2009 and Danborno et al., 2018).  
 
 
Fig. 5: The relaxation rate of forceps denuded vessels and L-
NAME treated vessels following treatment with U46619 (0.5 
µM). SQ29548 (3.0 µM) relaxation did not show significant 
difference (NS) between E+ and E- in both forceps denuded 
and L-NAME treated vessels (n= 22). 
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Fig. 6: The relative strength of contraction of vessels treated with KCl, U46619 and PE. Treatment with SQ29548 was given 
after exposure to the initial KCl, U46619 and PE and before exposure to the final KCl. All data are compared against the initial 
KCl contraction. A, B and C (respectively) denote endothelium intact (n= 6), endothelium denuded (n = 11) and L-NAME treated 
endothelium (n=11). 
 
In our previous paper (Danborno et al., 2018), we 
reported that inhibition of the Rho-kinase pathway with 
the Rho-kinase inhibitor Y-27632 shortens the 
relaxation phase of U46619 treated VSM. In these series 
of experiments, aortic vessels stimulated with U46619, 
also relaxed at a faster rate when treated with SQ29548 
compared to the untreated vessels, P< 0.0001 (Fig. 4). 
This observation was also reported by Ogletree et al. 
(1985) and Krauss et al. (1996). Our data support the 
hypothesis that the use of the TP receptor antagonist, 
SQ29548, would be an effective method for increasing 
the rate of relaxation of TxA2 mimetic-stimulated VSM. 
Moreover, because the use of the receptor antagonist 
SQ29548 should prevent U46619 from binding to the 
receptor, our data suggests that persistent binding of 
U46619 to the TP receptor is at least partially 
responsible for the prolonged contraction of U46619-
stimulated VSM.  
Endogenous NO is the main relaxing factor in vascular 
endothelium. However, in situations where the 
endothelium can no longer produce NO due to 
pathological conditions, there is need for finding ways 
to bring about relaxation after an induced contraction by 
TxA2 which is usually persistent.  It is pertinent to find 
an antagonist that can not only be selective and efficient, 
but also safe. This led us to hypothesize that NO aids the 
faster relaxation brought about by SQ29548. In order to 
test our hypothesis, in a separate set of experiments, the 
endothelial effect was removed either by using forceps 
to denude the endothelium (Liu et al., 2009), or using L-
NAME to inhibit the synthesis of NO by the endothelium 
(Kopincova et al., 2012 and Danborno et al., 2018). 
Following treatment with U46619, our most interesting 
finding was that, no significant differences was observed 
in the rate of recovery between endothelium-intact 
vessels (E+) and endothelium-denuded or L-NAME 
treated vessels (E-) (Fig. 5). This suggest that the 
elimination of NO did not affect the actions of SQ29548 
in displacing the binding of U46619 from the TP 
receptors and bringing about a faster relaxation.   
The vessels were subjected to KCl contractions so as to 
give reference to the other contractile agents. High KCl 
is a strong depolarizing agent while PE is an exogenous 
drug that stimulates the α-1 adrenergic receptor and 
contracts smooth muscle with a cellular transduction 
mechanism that is similar to TxA2 (Somlyo and Somlyo 
2000 and Fukata et al., 2001). The depolarization in 
VSMCs caused by high KCl induces L-type voltage-
dependent Ca2+ channels to open on the surface of 
vascular smooth muscle cells, allowing extracellular 
Ca2+ to enter the cell. Resulting increases in intracellular 
Ca2+ concentration can activate other second messengers 
such as protein kinase C (Woodsome et al., 2006). We 
should point out however that when vessels were treated 
with high KCl in these experiments, the vessels relaxed 
quickly after KCl was removed from the organ bath. 
Interestingly, we observed that the strength of the final 
KCl contractions were higher than the initial KCl 
contractions, this suggest that not only were the vessels 
active throughout the period of the experiment but also 
that SQ29548 did not have effect on the contractile 
actions of KCl in VSM. Further work is needed to define 
the mechanism for these observations.   
 
CONCLUSION  
Cardiovascular diseases result in more deaths worldwide 
than any other single factor. Because of this, it is 
important to investigate mechanisms that may prevent 
its detrimental outcome. Thromboxane A2 has been 
implicated as a factor leading to some cardiovascular 
disease, its attenuation should be investigated as a 
possible way to reduce heart disease-related deaths. This 
study presented evidence that agents capable of 
attenuating the rate of recovery from TxA2 sustained 
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contraction could have beneficial effects in the 
management of cardiovascular diseases. 
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